drugset
drugset / Trial / NCT00792571

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571 ↗

Phase 2 Completed 18 enrolled Lung Biotechnology PBC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.

Timeline

Start
2009-02-28
Primary completion
2013-11-30
Completion
2013-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Beraprost Small molecule 60 ug —

Indications

pulmonary arterial hypertension